Literature DB >> 25747387

Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.

Nianli Liu1, Tianran Chen2, Xiaohong Wang2, Darong Yang2, Binbin Xue2, Haizhen Zhu3.   

Abstract

To investigate TRAIL resistance mechanisms in hepatocellular carcinoma (HCC), we isolated a stable TRAIL-resistant sub-population of the HCC cell line LH86, designated LH86-TR. Differential activation of AKT was not responsible for acquisition of TRAIL resistance. Cells with both congenital and acquired resistance to TRAIL exhibited increased Msi1 expression, which conferred TRAIL resistance by activating ERK. Forced expression of Msi1 decreased the sensitivity of HCC cells to TRAIL both in vitro and in vivo. Conversely, shRNA-mediated depletion of Msi1 enhanced TRAIL efficacy. SiRNA-mediated depletion of ERK overcame TRAIL resistance. Hence, we conclude that Msi1 is a mediator of TRAIL resistance in HCC cells.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug resistance; ERK; Hepatocellular carcinoma; Msi1; Tumor necrosis factor-related apoptosis-inducing ligand

Mesh：

Substances：

Year:  2015        PMID： 25747387     DOI： 10.1016/j.febslet.2015.02.026

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  8 in total

1.  [Musashi-1 positively regulates growth and proliferation of hepatoma cells in vitro].

Authors:  Jie Li; Kun Yan; Yi Yang; Hua Li; Zhidong Wang; Xin Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

2.  ISG12a and its interaction partner NR4A1 are involved in TRAIL-induced apoptosis in hepatoma cells.

Authors:  Nianli Liu; Zhiyuan Wu; Aoxing Chen; Dafei Chai; Liantao Li; Longzhen Zhang; Junnian Zheng
Journal:  J Cell Mol Med       Date:  2019-03-01       Impact factor: 5.310

Review 3.  Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.

Authors:  Ehsan Razeghian; Wanich Suksatan; Heshu Sulaiman Rahman; Dmitry O Bokov; Walid Kamal Abdelbasset; Ali Hassanzadeh; Faroogh Marofi; Mahboubeh Yazdanifar; Mostafa Jarahian
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

4.  Correlation between Polymorphism of TRAIL Gene and Condition of Intervertebral Disc Degeneration.

Authors:  Shimin Xu; Ting Liang; Shuzhong Li
Journal:  Med Sci Monit       Date:  2015-08-06

5.  Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.

Authors:  Hsiao-Yun Chen; Liang-Ting Lin; Mong-Lien Wang; Shu-Hsien Lee; Ming-Long Tsai; Chi-Chang Tsai; Wei-Hsiu Liu; Tzu-Chien Chen; Yi-Ping Yang; Yi-Yen Lee; Yuh-Lih Chang; Pin-I Huang; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou; Ming-Teh Chen
Journal:  Oncotarget       Date:  2016-07-05

6.  CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3.

Authors:  Xiaoxin Jin; Lifeng Cai; Changfa Wang; Xiaofeng Deng; Shengen Yi; Zhao Lei; Qiangsheng Xiao; Hongbo Xu; Hongwu Luo; Jichun Sun
Journal:  Cell Death Dis       Date:  2018-02-23       Impact factor: 8.469

7.  Upregulation of musashi1 increases malignancy of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway and predicts a poor prognosis.

Authors:  Qiuhua Liu; Cuijie Zhou; Bo Zhang
Journal:  BMC Gastroenterol       Date:  2019-12-30       Impact factor: 3.067

8.  Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-β-Mediated JAK/STAT1 Pathway in vitro.

Authors:  Chun Sung Byun; Soonjae Hwang; Sung-Hun Woo; Moon Young Kim; Jin Suk Lee; Jong In Lee; Jee Hyun Kong; Keum Seok Bae; Il Hwan Park; Sung Hoon Kim; Young Woo Eom
Journal:  Int J Med Sci       Date:  2020-02-18       Impact factor: 3.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.